Imitrex

Rediff.com » News » Imitrex

News for Imitrex

Business

Imitrex delay: Ranbaxy may lose up to Rs 300 cr

Drug major Ranbaxy Laboratories could suffer a potential revenue loss to the tune of Rs 300 crore (Rs 3 billion) due to delay in receiving approval from the US Food and Drug Administration (FDA)......

Indian generics profit from Glaxo patent expiry

GlaxoSmithKline Plc's anti-migraine drug brand, Imitrex, is turning out to be a good revenue earner for Indian generic companies, as the US Food and Drug Administration has given almost half of the......

Dr Reddy's posts Rs 522-crore net loss

Dr Reddy's Laboratories, the country's second biggest drug maker, revealed an unexpected consolidated net loss of Rs 522 crore in the October-December quarter, due to a writedown of intangible......

Glaxo's strategy may limit gains for Indian firms

Global pharma major GlaxoSmithKline's strategy of launching an improved version of the migraine drug, Imitrex, after having an out-of-court settlement with Dr Reddy's and Ranbaxy Laboratories over......

Indian drug makers maintain pace of US mktg nod

Twenty five Indian generic drug makers got a little over 200 approvals from the US Food and Drug Administration in 2009, half a dozen more than the number approved in 2008. This increase is despite......

Rediff News

Imitrex

News for Imitrex

Imitrex delay: Ranbaxy may lose up to Rs 300 cr

Indian generics profit from Glaxo patent expiry

Dr Reddy's posts Rs 522-crore net loss

Glaxo's strategy may limit gains for Indian firms

Indian drug makers maintain pace of US mktg nod

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS